000			02791na a2200349 4500
003			PC4295
005			20210706062654.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
010			_a
024			_a
040			_cH12O
041			_aspa
100			_91249 _aArribas Ynsaurriaga, Fernando _eCardiología
100			_9163 _aRuiz Cano, María José _eCardiología
100			_aCortina Romero, José María _91245 _eCirugía Cardiovascular
100			_91250 _aDelgado Jiménez, Juan Francisco _eCardiología
100			_aLópez Gil, María _91253 _eCardiología
100			_9612 _aSáenz de la Calzada Campo, Carlos _eCardiología
100			_aGómez Sánchez, Miguel Ángel _91237 _eCardiología
245	0	0	_aImplante de desfibrilador como prevención primaria de muerte súbita en pacientes en lista de espera de trasplante cardiaco: experiencia de un centro _h[artículo]
260			_bRevista Española de Cardiología, _c2011
300			_a64(3):240-242.
337			_a
500			_aFormato Vancouver: Bastante Valiente T, Cano MJ, Delgado JF, Gil ML, Arribas F, Sánchez MA, et al. Implante de desfibrilador como prevención primaria de muerte súbita en pacientes en lista de espera de trasplante cardiaco: experiencia de un centro. Rev Esp Cardiol. 2011;64(3):240-2.
501			_aPMID: 21315501
504			_aContiene 13 referencias.
520			_aPatients who are on a waiting list for cardiac transplantation often have a clinical profile that satisfies current recommendations for the implantation of an implantable cardioverter-defibrillator for the primary prevention of sudden death. The prospect that transplantation may take place within the short-to-medium term puts the effectiveness of this therapy in doubt. We investigated the incidence of therapy delivered by implantable cardioverter-defibrillators implanted for primary prevention in patients awaiting cardiac transplantation. Recent changes in the incidence of sudden death at our center were also investigated. Data on 308 patients listed for heart transplantation between 1998 and 2008 were reviewed. An implantable cardioverter-defibrillator was indicated for primary prevention at initial evaluation in 17 patients. Of these, 53% received appropriate implantable cardioverter-defibrillator therapy while carrying an implantable cardioverter-defibrillator for a mean period of 7.8 months (±4.8). Only one patient received inappropriate therapy and none had any complications associated with device use. The frequency of sudden death has decreased over the course of recent years.
710			_9119 _aServicio de Cardiología
710			_9353 _aServicio de Cirugía Cardiovascular
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc4295.pdf _ySolicitar documento
942			_2ddc _cART _n0
999			_c4295 _d4295